title: Early renal injury after myeloablative cord blood transplantation in adults.
abstract: We report a retrospective analysis of acute renal failure (ARF) in a group of 54 adult patients with hematological malignancies treated with unrelated cord blood transplantation (CBT) after myeloablative conditioning. All patients received four fractionated 12 Gy total body irradiation and chemotherapy as myeloablative conditioning. ARF was defined as the doubling serum creatinine occurring within the first 100 days after CBT. A statistically significant decrement of renal function from baseline was observed in days between 11 and 20. ARF occurred in 27.8% of patients. Although no difference was seen in maximum cyclosporine trough levels, the maximum of vancomycin (VCM) trough levels were significantly higher in patients with ARF (p = 0.01). Our result suggests that it is important to monitor VCM dosing more strictly with pharmacokinetic assessment, especially in days 11 - 20, when the most frequently observed declining renal function.
authors.affiliation: Department of Pharmacy, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mae
authors.forename: Jun
authors.initials: J
authors.lastname: Ooi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takahashi
authors.forename: Akira
authors.initials: A
authors.lastname: Tomonari
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Tsukada
authors.forename: Takaaki
authors.initials: T
authors.lastname: Konuma
authors.forename: Emi
authors.initials: E
authors.lastname: Hongo
authors.forename: Seiko
authors.initials: S
authors.lastname: Kato
authors.forename: Senji
authors.initials: S
authors.lastname: Kasahara
authors.forename: Maki
authors.initials: M
authors.lastname: Oiwa-Monna
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Kurokawa
authors.forename: Arinobu
authors.initials: A
authors.lastname: Tojo
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Asano
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D016572:Cyclosporine / Q000008:administration & dosage; D005260:Female; D019337:Hematologic Neoplasms / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000009:adverse effects* / Q000379:methods; D014640:Vancomycin / Q000008:administration & dosage / Q000633:toxicity*; D014916:Whole-Body Irradiation
chemical_list: D000970:Antineoplastic Agents; D014640:Vancomycin; D016572:Cyclosporine